AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 587 businesses audited.
Medical Devices, Pharma & Biotech BS: VABYSMO (Genentech) (vabysmo.com)
This is a high-substance, low-BS pharmaceutical asset that prioritizes regulatory compliance and clinical data over marketing air. While it employs standard patient-centric cliches, it anchors every emotional hook in rigid, quantitative clinical proof.
Replace the generic ‘Open Up Your World’ H3 headings with specific outcome headers like ‘Sustained Vision Gains over 12 Months.’ Provide direct links to peer-reviewed publications in the Lancet or NEJM rather than relying on ‘data on file’ for market share statistics. Add ClinicalTrials.gov identifiers (e.g., NCT numbers) directly next to clinical outcome summaries for maximum transparency. Ensure that the ‘data on file’ from June 2025 is updated as it approaches the ‘stale’ 12-month threshold relative to the current 2026 system date.
The site exhibits high information density with a low fluff-to-substance ratio. Headings such as ‘#1 PRESCRIBED FDA-APPROVED TREATMENT FOR WET AMD’ are supported by specific data sources like Verana Health patient share analysis (Apr-Jun 2025). Body text is saturated with quantitative clinical outcomes, such as gaining ‘5 letters at 1 month’ and ‘6 letters over 1 year,’ effectively avoiding vague power words in favor of measurable metrics.
If your canonical, redirect, and final URL disagree, AI cannot determine which version to trust. Verify your Identity Stability for free and detect conflicts before they fragment your authority.
There is virtually zero semantic drift between pages. The homepage establishes VABYSMO as a treatment for wet AMD, DME, and RVO, and the sub-pages (specifically the WAMD page) provide deeper technical and clinical dives into those exact indications. The Spanish version maintains identical claims, ensuring cross-linguistic messaging consistency.
Transition from a collection of strings to a machine verifiable identity. Generate your Clinical SEO Strategy to establish a robust Knowledge Graph Topology and eliminate semantic black holes.
The site avoids trust theatre by prominently displaying ‘Important Safety Information’ and clearly labeling patient testimonials with ‘Actor portrayal’ and ‘Patient compensated by Genentech.’ While it cites ‘data on file’ for its market share claims, it backs efficacy claims with clinical study averages (e.g., gains of 5-13 letters), providing a high degree of transparency for a commercial medical site.
Proof density is extremely high. Every major efficacy claim is footnoted with clinical trial specifics, including letter gain counts, timeframes (1 month to 1 year), and patient population counts (e.g., ‘7 out of 664 patients’). The site provides a verifiable evidence path for nearly every assertion made in the hero sections.
For a high volume editorial domain example, open the Search Engine Journal Semantic HTML audit. View the SEJ Semantic HTML Audit to see how template drift and structural noise impact AI chunking.
The primary industry cliché is the value proposition ‘Open Up Your World,’ which is a standard pharmaceutical trope found in many vision-related treatments. However, this is balanced by unique clinical differentiators like being the ‘only FDA-approved treatment thought to block 2 causes of vision loss (VEGF and Ang-2),’ which prevents the content from being entirely copy-pasteable onto a competitor site.
Authority is well-established through robust schema_json identifying the parent organization (Genentech) and detailed prescribing information. The absence of named individual experts (e.g., lead researchers) is standard for drug-branded sites, as the authority is derived from the FDA approval status rather than personal digital footprints.
There is no disconnect between marketing tone and demonstrated performance; the site repeatedly qualifies its vision-improvement claims with ‘on average’ and ‘similar to aflibercept 2 mg.’ These performance claims are directly tied to clinical trial results cited in the footer notes and safety sections.
Medical Devices, Pharma & Biotech BS: VABYSMO (Genentech) (vabysmo.com)
The content perfectly aligns with the Pharma & Biotech industry, characterized by heavy regulatory disclosure, clinical trial data citations, and a focus on therapeutic mechanisms of action. The use of ‘faricimab-svoa’ and detailed safety protocols confirms the pharmaceutical nature of the entity.
AI does not interpret your layout visually — it interprets your structure mathematically. Explore the Semantic HTML Technical Framework to understand how heading logic, boundaries, and DOM depth determine what an LLM can retrieve.
“The low BS score is driven by high specificity in performance claims and an absence of semantic drift. Minor points were deducted for the use of generic industry value prop cliches ('Open Up Your World') and the use of 'data on file' citations which are less transparent than public database links.”